Early escalation and late de-escalation of antiplatelet therapy is not beneficial in patients after complex stenting


Notes to editor

This press release accompanies both a presentation and an ESC press conference at ESC Congress 2025.  

It does not necessarily reflect the opinion of the European Society of Cardiology.  

 

ESC Press Office
Tel: +33 6 61 40 18 84   
Email: press@escardio.org

Follow European Society of Cardiology News on LinkedIn

Funding: This study was funded by the CardioVascular Research Foundation and ChongKunDang Pharmaceutical Corp. 

Disclosures: Professor Park reports research grants for this trial from the CardioVascular Research Foundation and ChongKunDang Pharmaceutical Corp. and reports research grants for other research projects and speaker fees from Abbott Vascular, Medtronic, Boston Scientific, Daiichi-Sankyo, Edwards Lifesciences, ChongKunDang Pharm, Daewoong Pharm and HK inno.N Co., Ltd. 

 

References and notes: 

1‘TAILORED-CHIP: Tailored antiplatelet therapy for complex high-Risk PCI’ presented during HOT LINE 7 on 31 August 2025 at 16:30 to 16:40 in Madrid (Main Auditorium). 

 

About ESC Congress 2025 

It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Madrid and online – from 29 August to 1 September 2025. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org. 

 

About the European Society of Cardiology

The ESC brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.


Continue Reading